Protected: Edoxaban▼ in patients with atrial fibrillation and co-existing cardiovascular disease

Br J Cardiol 2019;26(suppl 2):S4–S9doi:10.5837/bjc.2019.s08
Click any image to enlarge
Sponsorship Statement:

The development of this supplement was commissioned and funded by Daiichi Sankyo UK Ltd, which also checked the manuscript for compliance with the ABPI Code of Practice. Editorial control of content was with The British Journal of Cardiology.

Prescribing information for Lixiana® (edoxaban) and adverse event reporting details can be found here.

Date of preparation: July 2019
Job bag number: EDX/19/0433

There is no excerpt because this is a protected post.

This content is password protected. To view it please enter your password below:

Disclaimer: Medinews Cardiology Limited advises healthcare professionals to consult up-to-date Prescribing Information and the full Summary of Product Characteristics available from the manufacturers before prescribing any product. Medinews Cardiology Limited cannot accept responsibility for any errors in prescribing which may occur.